Active TGF-β1 correlates with myofibroblasts and malignancy in the colorectal adenoma-carcinoma sequence

Cancer Science

Volumn 100, Issue 4, 2009, Pages 663-670

  Hawinkels, Lukas J A C ^a   Verspaget, Hein W ^a   van der Reijden, Johan J ^a   van der Zon, Johanna M ^a   Verheijen, Jan H ^b   Hommes, Daniel W ^a   Lamers, Cornelis B H W ^a   Sier, Cornelis F M ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b TNO   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

GELATINASE A; GELATINASE B; PLASMINOGEN ACTIVATOR INHIBITOR 1; SMOOTH MUSCLE ACTIN; TRANSFORMING GROWTH FACTOR BETA1; UROKINASE; ACTIN; DESMIN; KERATIN; SMAD2 PROTEIN; SMAD2 PROTEIN, HUMAN; TUMOR MARKER; VIMENTIN;

ARTICLE; CANCER GRADING; CANCER STAGING; CANCER SURVIVAL; COLON MUCOSA; COLORECTAL ADENOMA; COLORECTAL CARCINOMA; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MYOFIBROBLAST; PATHOPHYSIOLOGY; PRECANCER; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN TARGETING; RECTUM MUCOSA; TISSUE DISTRIBUTION; TISSUE LEVEL; ADENOMA; CARCINOMA; CELL STRAIN HT29; COLORECTAL TUMOR; FIBROBLAST; IMMUNOHISTOCHEMISTRY; METABOLISM; PATHOLOGY; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; SMOOTH MUSCLE;

ACTINS; ADENOMA; CARCINOMA; COLORECTAL NEOPLASMS; DESMIN; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBROBLASTS; HT29 CELLS; HUMANS; IMMUNOHISTOCHEMISTRY; KERATINS; MALE; MUSCLE, SMOOTH; PLASMINOGEN ACTIVATOR INHIBITOR 1; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SMAD2 PROTEIN; TRANSFORMING GROWTH FACTOR BETA1; TUMOR MARKERS, BIOLOGICAL; UROKINASE-TYPE PLASMINOGEN ACTIVATOR; VIMENTIN;

EID: 67449098428     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2009.01100.x     Document Type: Article

References (42)

1. Gout S, Huot J. Role of cancer microenvironment in metastasis: Focus on colon cancer. Cancer Microenviron 2008; 1: DOI 10. 1007/ s12307-008-0007-2.
2. Park CC, Bissell MJ, Barcellos-Hoff MH. The influence of the microenvironment on the malignant phenotype. Mol Med Today 2000; 6: 324-9.
3. Nielsen JD, Moeslund M, Wandall HH et al. Influences of tumor stroma on the malignant phenotype. J Oral Pathol Med 2008; 7: 412-6.
4. Ohtani H. Pathophysiologic significance of host reactions in human cancer tissue: Desmoplasia and tumor immunity. Tohoku J Exp Med 1999; 187: 193-202.
5. Orimo A, Weinberg RA. Heterogeneity of stromal fibroblasts in tumors. Cancer Biol Ther 2007; 6: 618-19.
6. Powell DW, Adegboyega PA, Di Mari JF et al. Epithelial cells and their neighbors I. Role of intestinal myofibroblasts in development, repair, and cancer. Am J Physiol Gastrointest Liver Physiol 2005; 289: G2-7.
7. Kalluri R, Zeisberg M. Fibroblasts in cancer. Nat Rev Cancer 2006; 6: 392-401.
8. Lieubeau B, Heymann MF, Henry F et al. Immunomodulatory effects of tumor-associated fibroblasts in colorectal-tumor development. Int J Cancer 1999; 81: 629-36.
9. De Wever O, Nguyen QD, Van Hoorde L et al. Tenascin-C and SF/HGF produced by myofibroblasts in vitro provide convergent pro-invasive signals to human colon cancer cells through RhoA and Rac. FASEB J 2004; 18: 1016-18.
10. De Wever O, Mareel M. Role of tissue stroma in cancer cell invasion. J Pathol 2003; 200: 429-47.
11. Huet E, Vallee B, Szul D et al. Extracellular matrix metalloproteinase inducer/CD147 promotes myofibroblast differentiation by inducing alpha-smooth muscle actin expression and collagen gel contraction: implications in tissue remodeling. FASEB J 2008; 22: 1144-54.
12. Ronnov-Jessen L, Petersen OW, Koteliansky VE et al. The origin of the myofibroblasts in breast cancer. Recapitulation of tumor environment in culture unravels diversity and implicates converted fibroblasts and recruited smooth muscle cells. J Clin Invest 1995; 95: 859-73.
13. Wipff PJ, Rifkin DB, Meister JJ et al. Myofibroblast contraction activates latent TGF-β1 from the extracellular matrix. J Cell Biol 2007; 179: 1311-23.
14. Ten Dijke P, Arthur HM. Extracellular control of TGF-β signalling in vascular development and disease. Nat Rev Mol Cell Biol 2007; 8: 857-69.
15. Barcellos-Hoff MH, Ewan KB. Transforming growth factor-beta and breast cancer: Mammary gland development. Breast Cancer Res 2000; 2: 92-9.
16. Hawinkels LJ, Verspaget HW, van Duijn W et al. Tissue level, activation and cellular localisation of TGF-β1 and association with survival in gastric cancer patients. Br J Cancer 2007; 97: 398-404.
17. Muraoka-Cook RS, Dumont N, Arteaga CL. Dual role of transforming growth factor-β in mammary tumorigenesis and metastatic progression. Clin Cancer Res 2005; 11: 937s-43s.
18. Leivonen SK, Kahari VM. Transforming growth factor-β signaling in cancer invasion and metastasis. Int J Cancer 2007; 121: 2119-24.
19. Desmouliere A, Geinoz A, Gabbiani F et al. Transforming growth factor-β1 induces alpha-smooth muscle actin expression in granulation tissue myofibroblasts and in quiescent and growing cultured fibroblasts. J Cell Biol 1993; 122: 103-11.
20. Adegboyega PA, Mifflin RC, DiMari JF et al. Immunohistochemical study of myofibroblasts in normal colonic mucosa, hyperplastic polyps, and adenomatous colorectal polyps. Arch Pathol Laboratory Med 2002; 126: 829-36.
21. Lewis MP, Lygoe KA, Nystrom ML et al. Tumour-derived TGF-β1 modulates myofibroblast differentiation and promotes HGF/SF-dependent invasion of squamous carcinoma cells. Br J Cancer 2004; 90: 822-32.
22. Sier CF, Verspaget HW, Griffioen G et al. Imbalance of plasminogen activators and their inhibitors in human colorectal neoplasia. Implications of urokinase in colorectal carcinogenesis. Gastroenterology 1991; 101: 1522-8.
23. Kubben FJ, Sier CF, van Duijn W et al. Matrix metalloproteinase-2 is a consistent prognostic factor in gastric cancer. Br J Cancer 2006; 94: 1035-40.
24. Kobayashi R, Tawata M, Field JB. Actin in Triton-insoluble cytoskeleton of thyroid. Metabolism 1982; 31: 133-8.
25. Lowry OH, Rosebrough NJ, Farr AL et al. Protein measurement with the Folin phenol reagent. J Biol Chem 1951; 193: 265-75.
26. Tsushima H, Kawata S, Tamura S et al. High levels of transforming growth factor β1 in patients with colorectal cancer: Association with disease progression. Gastroenterology 1996; 110: 375-82.
27. Bellone G, Carbone A, Tibaudi D et al. Differential expression of transforming growth factors-β1-β2 and -β3 in human colon carcinoma. Eur J Cancer 2001; 37: 224-33.
28. Langenskiold M, Holmdahl L, Falk P et al. Increased TGF-β1 protein expression in patients with advanced colorectal cancer. J Surg Oncol 2008; 97: 409-15.
29. Mesker WE, Junggeburt JM, Szuhai K et al. The carcinoma-stromal ratio of colon carcinoma is an independent factor for survival compared to lymph node status and tumor stage. Cell Oncol 2007; 29: 387-98.
30. Nakayama H, Enzan H, Miyazaki E et al. The role of myofibroblasts at the tumor border of invasive colorectal adenocarcinomas. Jpn J Clin Oncol 1998; 28: 615-20.
31. Illemann M, Hansen U, Nielsen HJ et al. Leading-edge myofibroblasts in human colon cancer express plasminogen activator inhibitor-1. Am J Clin Pathol 2004; 122: 256-65.
32. Schmitt M, Mengele K, Schueren E et al. European Organisation for Research and Treatment of Cancer (EORTC) Pathobiology Group standard operating procedure for the preparation of human tumour tissue extracts suited for the quantitative analysis of tissue-associated biomarkers. Eur J Cancer 2007; 43: 835-44.
33. Abergel A, Sapin V, Dif N et al. Growth arrest and decrease of alpha-SMA and type I collagen expression by palmitic acid in the rat hepatic stellate cell line PAV-1. Dig Dis Sci 2006; 51: 986-95.
34. Micke P, Ostman A. Tumour-stroma interaction: Cancer-associated fibroblasts as novel targets in anti-cancer therapy? Lung Cancer 2004; 45 (Suppl. 2): S163-75.
35. Hofmeister V, Schrama D, Becker JC. Anti-cancer therapies targeting the tumor stroma. Cancer Immunol Immunother 2008; 57: 1-17.
36. Sier CF, Fellbaum C, Verspaget HW et al. Immunolocalization of urokinase-type plasminogen activator in adenomas and carcinomas of the colorectum. Histopathology 1991; 19: 231-7.
37. Ornstein DL, MacNab J, Cohn KH. Evidence for tumor-host cooperation in regulating MMP-2 expression in human colon cancer. Clin Exp Metastasis 1999; 17: 205-12.
38. Sier CF, Zuidwijk K, Zijlmans HJ et al. EMMPRIN-induced MMP-2 activation cascade in human cervical squamous cell carcinoma. Int J Cancer 2006; 118: 2991-8.
39. Blavier L, Declerck YA. Considering the critical interface between tumor cells and stromal cells in the search for targets for anticancer therapy. Cancer Cell 2005; 7: 408-9.
40. Bisson C, Blacher S, Polette M et al. Restricted expression of membrane type 1-matrix metalloproteinase by myofibroblasts adjacent to human breast cancer cells. Int J Cancer 2003; 105: 7-13.
41. Cauwe B, Van den Steen PE, Opdenakker G. The biochemical, biological, and pathological kaleidoscope of cell surface substrates processed by matrix metalloproteinases. Crit Rev Biochem Mol Biol 2007; 42: 113-85.
42. Jenkins G. The role of proteases in transforming growth factor-β activation. Int J Biochem Cell Biol 2008; 40: 1068-78.